RxDoctor Payments Data

Ngoc-Ha Nguyen, MD

Internal Medicine · Annandale, VANPI 1750346870

Payments from drug & device makers

$9,233in general payments, 2019–2025

Across 499 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Gilead$1K
  • Amgen$878
  • AstraZeneca$699
  • Pfizer$678
  • Novo Nordisk$608
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$9,16399%
  • Education$511%
  • Gifts$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,233 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$437,835
Medicare patients
586
Services billed
6,195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab168$291,701
OzempicSemaglutide49$102,217
JanuviaSitagliptin Phosphate56$80,291
VascepaIcosapent Ethyl93$78,823
JardianceEmpagliflozin40$67,631
EliquisApixaban46$54,758
VemlidyTenofovir Alafenamide22$35,242
GemtesaVibegron48$34,400
TrulicityDulaglutide20$27,212
Omega-3 Acid Ethyl Esters148$24,771
FarxigaDapagliflozin Propanediol22$23,464
LinzessLinaclotide15$18,187
Tenofovir Disoproxil Fumarate36$18,092
MyrbetriqMirabegron22$17,507
RestasisCyclosporine25$16,094

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$878$291,701168 claims
Novo NordiskOzempic$608$102,21749 claims
MerckJanuvia$195$80,29156 claims
Boehringer IngelheimJardiance$153$67,63140 claims
PfizerEliquis$678$54,75846 claims
AbbVieLinzess, Restasis, Synthroid$1,158$48,156182 claims
GileadVemlidy$1,022$35,24222 claims
Sumitomo Pharma America, Inc.Gemtesa$171$34,40048 claims
Lilly USA, LLCTrulicity$562$27,21220 claims
AstraZenecaFarxiga$699$23,46422 claims
Astellas Pharma US IncMyrbetriq$170$17,50722 claims
GSKTrelegy Ellipta$543$15,08816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Annandale

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →